back to Meetings page
Participants
Agenda
Background Materials
  • IMMPACT-XVI Slide Presentations

  • 1. Patient-reported pain and symptom measures, including psychological and sleep measures for Phase 2 and 3 trials
  • Robert Edwards, MD
  • 2. PROMIS measures and the NIH tool box for Phase 2 and 3 trials
  • Raymond Dionne, DDS, PhD
  • 3. Quantitative sensory testing (QST) for Phase 2 trials
  • Per Hansson, MD, DMSci, PhD
  • 4. Conditioned pain modulation (CPM) / descending noxious inhibitory controls (DNIC) for Phase 2 and 3 trials
  • Simon Haroutiunian, PharmD, PhD
  • 5.Response to pharmacologic challenge in Phase 2 and 3 trials
  • Martin Angst, MD
  • 6. Clinical testing and QST in Phase 3 trials
  • Roy Freeman, MD

  • 7. Bedside sensory testing
  • Nathaniel Katz, MD